M1117

Pharmacokinetics of Subcutaneously-administered CBX129801, A Long-acting Synthetic C-Peptide in Patients with Type 1 Diabetes Mellitus

Ahmed Kousba¹, Sue Griffith², Mark Milad³, Mark Daniels⁴, Howard Foyt⁴; ¹BioAgilytix, San Diego, CA, 92121. ²ClinPharma Services, Inc., San Diego, CA, 92127. ³Milad Pharmaceutical Consulting, Plymouth, MI, 48170. ⁴Cebix, Inc., La Jolla, CA, 92037.

ABSTRACT

Purpose:

To assess the pharmacokinetics (PK) of CBX129801, a long-acting synthetic C-peptide, following dose and $Log_{10} C_{max}$ was 1.116 (0.9631 to 1.268) and for $Log_{10} AUC_{\infty}$ was 1.154 (0.8709 to 1.437). subcutaneous (SC) injection in patients with type 1 diabetes mellitus (TIDM).

Methods:

study to assess the safety, tolerability, and PK of CBX129801 administered SC in patients with TIDM. (90% CI) for dose and Log₁₀ C_{max} was 1.150 (1.051 to 1.248) and for Log₁₀ AUC₁ was 1.148 (1.054 to Single doses of 0.3, 1.0, and 3.3 mg were evaluated in 3 sequential cohorts (A, B and C, respectively). 1.243). The T_{max} and t_{1/2} were similar following single and repeat dosing. Subjects were randomized to CBX129801 (n=8) or placebo (n=2) per cohort. Three weeks later, 4 additional doses (in Cohorts A and B) or 3 additional doses (in Cohort C) were administered at weekly **Conclusions:** intervals. Plasma CBX129801 concentrations were quantified by an ELISA and PK parameters were dose separately using the power-law model.

Results:

After single doses, median plasma CBX129801 T_{max} ranged from 3.11 to 4.93 days. The mean C_{max} values were 0.269, 0.975 and 4.13 nM for the 0.3, 1 and 3.3 mg doses, respectively. Corresponding mean AUC_{∞} values for the two higher doses were 14.5 and 60.4 nM·d, $t_{1/2}$ were 6.37 and 6.92 days, CL/F were 1.59 and 1.38 L/d and V₂/F were 14.3 and 12.7 L, respectively.

The $t_{1/2}$, AUC, CL/F and V/F were incalculable at the 0.3 mg dose since it was not possible to estimate λ_{j} . Dose proportionality assessment showed the slope (90% Confidence Interval; CI) for

After repeated doses, mean T_{max} ranged from 1.98 days to 2.99 days, mean C_{max} values were 0.718, 2.30, and 11.2 nM, mean C_{min} values were 0.469, 1.73, and 6.82 nM and mean AUC_T values were 4.31, 14.2, and 66.7 nM·d at the 0.3, 1.0, and 3.3 mg/week repeated doses, respectively. This was a phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending dose CBX129801 exposure following repeated doses was slightly more than dose proportional; the slope

determined by noncompartmental analysis. Dose proportionality was assessed for single and multiple CBX129801 exposure in patients with T1DM was approximately dose proportional, single dosing was predictive for multiple dosing, and the half-life supports weekly dosing.

Purpose

To assess the single and multiple dose pharmacokinetics (PK) of CBX129801 following subcutaneous (SC) injection in patients with type 1 diabetes mellitus (T1DM).

Introduction

Type 1 diabetes mellitus (TIDM) affects about 1.4 million people in the US and 10 to 20 million Preclinical and early clinical studies demonstrated that the administration of C-peptide showed worldwide (1, 2). In the US, 30,000 new cases are diagnosed annually and 40% of those protective effect against the long-term complications of TIDM, including DPN. However, the diagnosed are under the age of 20 years (3, 4). Type 1 diabetes is characterized by the body's short half-life of C-peptide aqueous formulation (~65 min) precludes its clinical applicability (7). inability to produce proinsulin and consequently both insulin and C-peptide. The plasma C-peptide Cebix Inc. is developing CBX129801, a long-acting PEGylated synthetic C-peptide that supports concentration in patients with TIDM is below 0.1 nM relative to the physiological range in healthy weekly SC dosing, to treat the long-term complications of diabetes. This poster presents the PK subjects of 0.4-6 nM (5, 6). Diabetic neuropathy (DPN) affects about half of all people with of CBX129801 in patients with TIDM (Clinical Trial Registration Number: NCT01293461). diabetes at some point in their lifetimes.

METHODS

Study:

A phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety, tolerability, and PK of CBX129801 administered SC in patients with TIDM.

Dose

Part 1: Escalating doses of 0.3, 1.0, and 3.3 mg were After review of the PK data from Part 1 of the dosing interval after the last dose.

Part 2:

administered in 3 sequential cohorts (A, B and study, in order to select a dose regimen to C, respectively). Within each cohort, subjects achieve a target C-peptide "replacement" were randomized to CBX129801 (n=8) or plasma concentration at steady-state, subjects placebo (n=2) and a single dose was in Part 2 (Cohort D) were randomized to administered. Three weeks later, 4 additional CBX129801 (n=29) or placebo (n=13). A doses (in Cohorts A and B) or 3 additional loading dose of 2.0 mg was administered and doses (in Cohort C) were administered at 1 week later, 12 maintenance doses of 0.8 mg weekly intervals. Blood samples were collected were administered at weekly intervals. Blood at the end of the predetermined times over samples were collected pre-dose (trough) for 672 hours. Pre-dose (trough) samples were the first and second doses, then before every include 1.00). collected for all doses and at the end of the other dose from the third through the eleventh doses and at the end of the dosing interval after the last dose.

Analytical Method

Plasma CBX129801 concentrations were quantified by an ELISA assay. PK Analysis

- Professional 6.1.1 (Pharsight Corp., Mountain View, CA, USA).
- with GraphPad Prism v 5.01 (GraphPad Inc., CA, USA).
- $\log C_{max}$ or $\log AUC =$

where $\log(\mu)$ and B, and ε are the intercept, slope and the random error, respectively. A slope of 1.00 indicates perfect dose proportionality, a slope of less than 1.00 or greater than 1.00 indicates less than or greater than dose proportional, respectively (90% CI for the slope should

Table 1

Summary of Plasma CBX129801 PK Parameters Following the First Dose in Part 1


Dose, mg	0.3		1.0	1.0		3.3		Dose, mg	0.3		1.0			3.3					
PK Parameter	n	Mean	%CV	n	Mean	%CV	n	Mean	%CV	PK Parameter	n	Mean	%CV	n	Mean	%CV	n	Mean	%CV
C _{max} , nM	3	0.269	7.24	8	0.975	23.4	8	4.13	43.3	C _{max} , nM	7	0.718	29.2	8	2.30	11.O	8	11.2	29.5
T _{max} , d*	3	3.11	(2.98-6.86)	8	4.91	(2.85-6.94)	8	4.93	(2.98-5.02)	C _{min} , nM	7	0.469	26.6	8	1.73	19.8	8	6.82	32.1
AUC _(O-T) , nM•d	3	1.38	51.9	8	11.8	32.1	8	49.7	41.4	C _{av} , nM	7	0.615	28.1	8	2.04	13.4	8	9.52	27.5
AUC _{t,sd} , nM•d	1	1.42	NC	8	5.28	28.6	8	22.4	45.6	T _{max} , d*	7	2.99	(0.972-7.00)	8	1.98	(0-3.03)	8	2.45	(1.90-4.94)
$AUC_{m,sd}$, nM•d	0	NC	NC	8	14.5	29.6	8	60.4	45.0	AUC _(O-T) , nM•d	7	8.14	37.1	8	26.9	21.8	8	154	36.1
%AUCextrap	0	NC	NC	8	19.0	26.7	8	16.2	55.6	AUC _{t,md} , nM•d	7	4.31	28.1	8	14.2	13.4	8	66.7	27.5
t _{1/2} , d	0	NC	NC	8	6.37	16.4	8	6.92	40.9	t _{1/2} , d	6	7.92	41.2	8	6.35	16.0	8	6.33	27.8
CL/F, L/d	0	NC	NC	8	1.59	33.3	8	1.38	42.0	CL _{ss} /F, L/d	7	1.62	34.1	8	1.52	12.7	8	1.13	26.4
V _z /F, L	0	NC	NC	8	14.3	26.9	8	12.7	45.0	V _{z,ss} /F, L	6	21.8	84.1	8	13.7	12.5	8	10.4	44.8
t _{lag} , d*	3	0.997	(0.238-0.997)	8	0.239	(0.0833-0.253)	8	0.0844	(0-0.25)	$AUC_{\tau,md} / AUC_{\infty,sd}$	0	NC	NC	8	1.04	23.6	8	1.22	34.6
: - Not calculated										RC _{max}	2	3.29	12.5	8	2.44	19.4	8	3.01	39.2
<pre>kpressed as median and ra - Single Dose</pre>	inge									RAUC _τ	1	3.70	NC	8	2.90	30.2	8	3.41	45.2

sd - Single Dose

Figure 1

—— 0.3 mg (n = 8)

Mean (± SD) Plasma CBX129801 Concentration-Time **Profiles in Part**



Semi-Logarithmic Scale





Figure 2

Plasma CBX129801 C_{max} and AUC_∞ Versus CBX129801 Dose in Part 1 Following the First Subcutaneous Dose



• PK analyses were performed using noncompartmental method (8) with validated WinNonlin • Dose proportionality was examined using a power-law model (p value set at $p \ge 0.05$) (9, 10)

$$log(\mu) + \beta \times log dose + \epsilon$$

Figure 3

Plasma CBX129801 C_{max} and AUC, Versus CBX129801 Dose in Part 1 Following the Last Subcutaneous Dose




Table 1

Summary of Plasma CBX129801 PK Parameters Following the Last Dose (Fourth or the Fifth Dose) in Part 1

IC - Not calculated $_{\text{AUCT}}$ accumulation index for AUC calculated from AUC, nax accumulation index for C_{max} calculated from C_{max} Expressed as median and range

sd - Single Dose md - Multiple Dose

Table 3

			Slo	ope			
Parameter	n		Mean (SE)		90% CI	p-value (Slope=1)	
			Single	e Dose			
$\text{Log } C_{\text{max}}$		19 1.116 (0		.08775)	0.9631 to 1.268	0.2045	
$Log AUC_{\infty}$	16		1.154 (0.1607)		0.8709 to 1.437	0.3544	
			Multip	le Dose			
Log C _{max}	19 1.150 (0.0)5749)		1.051 to 1.248	0.0167	
_og AUCτ	23	1.148 (0.0	5481)		1.054 to 1.243	0.0133	

Table 4


Summary of Predose Plasma CBX129801 Concentrations (nM) in Part 2

Parameter	n	Mean (SE)	p-value (Slope=1)		
0	28	0.00	NC		
7	29	2.70	50.0		
14	29	2.38	43.6		
28	29	2.04	43.1		
42	29	1.97	37.6		
56	29	1.90	40.5		
70	29	1.73	37.1		
84	29	1,82	32.3		
EOS	29	NC	NC		

EOS - End of Study NC - Not Calculated Each subject received a single 2.0 mg SC loading dose followed by 11 weekly 0.8 mg SC doses starting on Day 8 (i.e., a total of 12 doses administered). The last dose was on Day

Figure 4

Mean Predose Plasma CBX12980[°] **Concentrations in Part 2**



Each subject received a single 2.0 mg SC loading dose followed one week later by 11 weekly 0.8 mg SC doses starting on Day 8 (i.e., a total of 12 doses administered).

Results

SINGLE AND MULTIPLE DOSE PK OF CBX129801

Single Ascending Dose

- Median T_{max} ranged from 3.11 to 4.93 days and the median t_{lag} ranged from 0.0844 to 0.997 days (i.e., 2 to 24 hours) (Table 1).
- Mean C_{max} values were 0.269, 0.975 and 4.13 nM for the 0.3, 1 and 3.3 mg doses, respectively. Mean AUC_m values were 14.5 and 60.4 nM•d, $t_{1/2}$ values were 6.37 and 6.92 days, CL/F values were 1.59 and 1.38 L/d and V₂/F values were 14.3 and 12.7 L for the 1.0 and 3.3 mg doses, respectively (Table 1).
- It was not possible to estimate λ_{7} for the 0.3 mg dose, so $t_{1/2}$, AUC_{\$\infty\$}, CL/F and V₇/F were incalculable.

ASSESSMENT OF CBX129801 DOSE PROPORTIONALITY

• After single doses, CBX129801 exposure was dose proportional with slope for Cmax of 1.116 and for AUC∞ was 1.154. The corresponding 90% CI were 0.9631 to 1.268 and 0.8709 to 1.437, respectively (Table 3 and Figure 2).

ASSESSMENT OF REPEATED DOSING

Figure 1). The mean RCmax (accumulation index for Cmax) values were 3.29, 2.44 and and 2). 3.01 for the 0.3, 1.0 and 3.3 mg/week doses, respectively. Corresponding mean RAUC (accumulation index for AUC) values were 3.70, 2.90 and 3.41 (Table 2).

ATTAINMENT OF STEADY-STATE

suggested that steady state was likely achieved by Day 28 as presented in Table 4 and 84 ranged from 1.73 to 2.04 nM (Table 4). displayed in Figure 4.

Conclusions

- All the doses assessed in the study were safe and well tolerated. CBX129801 exposure was dose proportional following the single doses and slightly greater
- than dose proportional following the repeated doses. • The T_{max} and $t_{1/2}$ were not dose dependent following single or repeated doses.
- The CL/F and V₂/F were not dose dependent following the single doses and appeared to decrease as the dose increases following the repeated doses.
- The mean $t_{1/2}$ ranged from 6.33 to 7.92 days which is 150x greater than the native Cpeptide $t_{1/2}$ and supports weekly SC dosing of CBX129801.

References

- 1. Atkinson MA, Maclaren NK. (1994). The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 331: 1428.
- 3353—3361.
- 3. The DIAMOND Project Group. (2006). Incidence and trends of childhood type 1 diabetes worldwide 1990—1999. Diabet Med 23: 857—866. 4. LaPorte R, Matsushima M, Chang Y. (1995). Diabetes in America. Chapter 3. Prevalence
- and Incidence of Insulin-Dependent Diabetes. Bethesda, MD: National Institute of Health. 5. Polonsky KS, Given BD, Van Cauter E. (1988). Twenty-four-hour profiles and pulsatile

patterns of insulin secretion in normal and obese subjects. J Clin Invest; 81: 442-448.

BioAgilytix





Multiple Ascending Dose

- Median T_{max} ranged from 1.98 days to 2.99 days and the mean $t_{1/2}$ values ranged from 6.33 to 7.92 days (Table 2). Tmax and $t_{1/2}$ were not dose dependent and were similar following single and repeat dosing (Tables 1 and 2). • Mean C_{max} values were 0.718, 2.30, and 11.2 nM, mean C_{min} values were 0.469, 1.73, and 6.82
- nM and mean AUC, values were 4.31, 14.2, and 66.7 nM·d for CBX129801 doses of 0.3, 1.0, and 3.3 mg/week, respectively. The mean CL_{sc}/F values were 1.62, 1.52 and 1.13 L/d and mean V_{zs}/F values were 21.8, 13.7 and 10.4 L for the 0.3, 1.0, and 3.3 mg/week doses, respectively (Table 2).
- CL_x/F and V_z/F appeared to decrease as the dose of CBX129801 increased (Table 2).
- After repeated doses, CBX129801 exposure was slightly greater than dose proportional with slope for C_{max} of 1.150 and for AUC_T of 1.148. The corresponding 90% CI were 1.051 to 1.248 and 1.054 to 1.243, respectively (Table 3 and Figure 3).
- Following repeated doses, CBX129801 exhibited moderate accumulation (Table 2 and \bullet The T_{max}, t_{1/2} CL/F and V_z/F did not change due to repeated dosing of CBX129801 (Tables 1)
- CBX129801 predose concentrations on Days 0, 7, 14, 28, 42, 56 and 70 in Part 2 Steady-state mean predose plasma CBX129801 concentrations between Day 28 and Day

- Moderate accumulation of CBX129801 was observed and is consistent with the long $t_{1/2}$. • Steady state was achieved by Day 28. • Using SC doses of 0.3 mg - 3.3 mg CBX129801 administered at weekly intervals, it is
- possible to achieve plasma CBX129801 concentrations in patients with T1DM that are broadly within the physiological range of C-peptide concentrations observed in nondiabetic individuals (0.4 nM - 6 nM).

- 1. Polonsky KS, Given BD, Hirsch L, et al. (1988). Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest; 81: 435-441.
- 2. Gale EA. (2002). The rise of childhood type 1 diabetes in the 20th century. Diabetes 51: 2. Cebix Incorporated Document Number CLN-10-129800-007. (2010). The pharmacokinetics of cSPM933 unmodified C-peptide in patients with type 1 diabetes. A dose range study. October 2010.
 - 3. Gibaldi, M. and Perrier, D. (1982). Pharmacokinetics, Second Edition, Marcel Dekker, Inc., New York.
 - 4. Gough, K., Hutchison, M., Keene, O., Byrom, B., Ellis, S., Lacey, L. and McKellar. J. (1995). Assessment of dose proportionality: Report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Info. J. 29:1039—1048.
 - 5. Klamerus, K. J., Maloney, K., Rudolph, R. L., Sisenwine, S. F., Jusko, W. J. and Chiang. S. T. (1992). Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O-desmethyl Metabolite. J. Clin. Pharmacol. 32:716 724.